Package Leaflet: Information for the User
Vitulia Glucosaline Serum 3.6%/0.3% Solution for Infusion
Glucose monohydrate, Sodium chloride
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Vitulia Glucosaline Serum is a solution for infusion that contains glucose and sodium chloride, and belongs to the pharmacotherapeutic group of solutions that affect the electrolyte balance - electrolytes with carbohydrates.
Vitulia Glucosaline Serum is indicated in:
Do not use Vitulia Glucosaline Serum:
Warnings and precautions:
Consult your doctor or nurse before using Vitulia Glucosaline Serum.
Glucosated solutions for intravenous infusion are generally isotonic. However, in the body, glucosated solutions can become extremely hypotonic physiologically due to the rapid metabolism of glucose.
Depending on the tonicity of the solution, the volume and rate of infusion, and the patient's initial clinical condition and ability to metabolize glucose, intravenous glucose administration can cause electrolyte disturbances, the most important of which is hyperosmotic hyponatremia.
Hyponatremia:
Patients with non-osmotic release of vasopressin (e.g., in critical states, pain, postoperative stress, infections, burns, and CNS diseases), patients with heart, liver, and kidney diseases, and patients exposed to vasopressin agonists have a special risk of experiencing acute hyponatremia after infusion of hypotonic solutions.
Acute hyponatremia can cause acute hyponatremic encephalopathy (cerebral edema) characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with cerebral edema have a special risk of suffering from severe, irreversible, and potentially fatal brain damage.
Children, women of childbearing age, and patients with reduced cerebral distensibility (e.g., in case of meningitis, intracranial hemorrhage, and cerebral contusion) have a special risk of suffering from severe and potentially fatal cerebral edema caused by acute hyponatremia.
Children
Vitulia Glucosaline Serum will be administered with caution to premature and full-term infants, due to immature renal function, to avoid excessive sodium retention.
Other medicines and Vitulia Glucosaline Serum
Tell your doctor or nurse if you are using or have recently used or may need to use any other medicine.
Certain medicines may interact with Vitulia Glucosaline Serum. In this case, it may be necessary to change the dose or interrupt treatment with one of the medicines.
It is important that you inform your doctor if you are using any of the following medicines:
Medicines that potentiate the effect of vasopressin
The following medicines increase the effect of vasopressin, which reduces the renal excretion of water without electrolytes and increases the risk of hospital hyponatremia after inadequately balanced treatment with intravenous infusion solutions:
Other medicines that are known to increase the risk of hyponatremia are also diuretics in general and antiepileptics such as oxcarbazepine.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or nurse before using this medicine.
Pregnancy
In case of pregnancy, your doctor will decide whether to use glucosaline solution, as it should be used with caution.
Excessive administration of solutions containing glucose during pregnancy can cause hyperglycemia, hyperinsulinemia, and fetal acidosis, and may be harmful to the newborn.
Vitulia Glucosaline Serum should be administered with special caution in pregnant women during labor, especially if administered in combination with oxytocin, due to the risk of hyponatremia.
Breastfeeding
There is no evidence to suggest that Vitulia Glucosaline Serum may cause adverse effects during the breastfeeding period in the neonate. However, it is recommended to use with caution during this period.
Driving and using machines
There is no indication that the administration of Vitulia Glucosaline Serum may affect the ability to drive or use machines.
This medicine will be used in a hospital or healthcare center by the responsible healthcare personnel.
Your doctor will decide the dose, frequency, and average infusion rate at which the solution will be administered, which will depend on your age, weight, clinical situation (particularly the state of hydration), blood glucose, hydroelectrolytic and acid-base balance, and the nature of any medication that may have been added to the solution.
The recommended dose is:
For adults: 500 mL to 3,000 mL every 24 hours.
For infants and children:
If you are given more Vitulia Glucosaline Serum than you should
If the administration of Vitulia Glucosaline Serum is not performed correctly and under control, some of the following signs of overdose may appear:
If this happens, treatment should be discontinued immediately and, depending on the severity, the following may be administered:
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, Vitulia Glucosaline Serum can cause side effects, although not everybody gets them.
Adverse reactions can occur associated with the administration technique, including fever, infection at the injection site, local reaction or pain, venous irritation, venous thrombosis or phlebitis extending from the injection site, extravasation, and hypervolemia. To avoid the risk of suffering from thrombophlebitis (inflammation of a vein due to a blood clot), it is recommended to vary the insertion site of the catheter (every 24-48 hours).
Hospital hyponatremia can cause irreversible brain damage and death due to the onset of acute hyponatremic encephalopathy.
Adverse reactions can be associated with the medications added to the solution; the nature of the added medications will determine the possibility of any other undesirable effect.
In case of adverse reactions, the infusion should be discontinued.
Reporting of side effects
If you experience any side effect, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report them directly through the Human Medicines Pharmacovigilance System: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Vitulia Glucosaline Serum after the expiration date stated on the packaging after EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Composition of Suero Glucosalino Vitulia
Appearance of the Product and Container Contents
Suero Glucosalino Vitulia is a solution for perfusion that is presented in low-density polyethylene bottles with 500 mL of solution. The clinical container contains 10 bottles.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Laboratorios ERN, S.A.
C/Perú, 228
08020 Barcelona, Spain
Manufacturer:
C/Gorgs Lladó, 188
Pol. Ind. Can Salvatella
08210 Barberá del Vallés (Barcelona), Spain
or
Parenteral Solution Industry Vioser S.A.
9th km Trikala-Larisa Nt.Rd.
42100 Trikala
Greece
Date of the Last Revision of this Prospectus: November 2023.
Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
-------------------------------------------------------------------------------------------
This information is intended only for doctors or healthcare professionals:
It may be necessary to monitor the fluid balance, serum glucose, serum sodium, and other electrolytes before and during administration, especially in patients with increased non-osmotic release of vasopressin (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients receiving concomitant medication with vasopressin agonists due to the risk of hyponatremia.
Monitoring of serum sodium is especially important when administering physiologically hypotonic solutions. Suero Glucosalino Vitulia may become extremely hypotonic after administration due to the metabolism of glucose in the body.
Administration Rate:
The perfusion rate is normally 40 mL/kg/24 h in adults.
In pediatric patients, the perfusion rate is 5 mL/kg/h on average, but this value varies with weight:
The perfusion rate should not exceed the patient's glucose oxidation capacity in order to avoid hyperglycemia. Therefore, the maximum dose ranges from 5 mg/kg/min for adults to 10-18 mg/kg/min for infants and children depending on age and total body mass.
The content of each container is for a single perfusion. The unused fraction should be discarded.
The perfusion solution should be visually inspected before use. The solution should be transparent, not contain precipitates, and the container should be intact. Do not administer otherwise.
Use an aseptic procedure to administer the solution and the addition of medications if necessary.
Before adding medications to the solution or administering simultaneously with other medications, it should be checked that there are no incompatibilities.
These solutions should not be administered through the same perfusion equipment that is being used, has been used, or will be used for the administration of blood, as there is a possibility of pseudoagglutination.
It has been described that the glucosaline solution with a glucose content of 3.6% and sodium chloride content of 0.3% is incompatible with mitomycin, due to the low pH of this solution.
Similarly, samples of incompatibility have been observed for different isotonic glucosaline solutions with: sodium amoxicillin, sodium heparin, sodium imipenem-cilastatin, and meropenem. However, these medications may be compatible with this type of solution depending on different factors such as the concentration of the medication (sodium heparin) or the time that elapses between dissolution and administration (sodium amoxicillin, sodium imipenem-cilastatin, and meropenem).
On the other hand, samples of incompatibility have been described when some medications are diluted in solutions that contain glucose, including: sodium ampicillin, amrinone lactate, sodium amoxicillin/acid clavulanic, interferon alfa-2b, procainamide hydrochloride. However, amrinone lactate or sodium amoxicillin/acid clavulanic can be injected directly into the injection point while these perfusion solutions are being administered.
The elimination of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.